A patient at 13 weeks gestation with refractory hyperemesis gravidarum on prednisolone 50 mg daily wants to taper and discontinue the steroid. How should the prednisolone be tapered and stopped?

Prednisolone Tapering for Hyperemesis Gravidarum at 13 Weeks

Taper prednisolone by 5-10 mg per week until reaching the lowest maintenance dose that controls symptoms, then discontinue once clinical improvement is sustained, typically by 16-20 weeks gestation. 1

Recommended Tapering Protocol

The RCOG Green-Top Guideline provides the clearest framework for steroid tapering in hyperemesis gravidarum 1:

• Start tapering: Reduce by 5-10 mg per week
• Goal: Find the lowest maintenance dose that controls symptoms
• Typical duration: Continue until symptoms resolve (median 20 weeks gestation in observational data)
• Continue antiemetics: Maintain previously effective antiemetics during the taper

Specific Tapering Schedule from 50 mg Daily

Based on the guideline recommendation of 5-10 mg weekly reductions 1, a practical approach would be:

• Week 1: 40 mg daily (reduce by 10 mg)
• Week 2: 30 mg daily (reduce by 10 mg)
• Week 3: 20 mg daily (reduce by 10 mg)
• Week 4: 15 mg daily (reduce by 5 mg)
• Week 5: 10 mg daily (reduce by 5 mg)
• Week 6: 5 mg daily (reduce by 5 mg)
• Week 7: Discontinue if symptoms remain controlled

Adjust the taper speed based on symptom recurrence—if vomiting returns during tapering, hold at the current dose for another week before attempting further reduction.

Critical Monitoring During Taper

While tapering, monitor for:

• Blood pressure: Check at each dose reduction (corticosteroids can cause hypertension) 1
• Glucose screening: Screen for gestational diabetes, as steroids increase blood glucose 1, 2
• Symptom recurrence: If vomiting returns, hold the taper and maintain the current dose for 1-2 weeks before attempting further reduction 1
• Weight gain: Ensure adequate maternal weight gain is maintained 3

Evidence Supporting This Approach

The RCOG guideline explicitly states that after converting from IV hydrocortisone to oral prednisolone 40-50 mg daily, "the dose [should be] gradually tapered (by 5-10 mg per week) until the lowest maintenance dose that controls the symptoms is reached" 1. This is the most authoritative and recent guidance available (2024).

Research data supports this gradual approach. In a series of 30 women with severe hyperemesis, steroid therapy was discontinued at a median gestation of 20 weeks after stepwise reduction 3. Another study used a 2-week taper from 48 mg methylprednisolone, though some patients required extension or reinstitution 4.

Common Pitfalls to Avoid

Do not taper too rapidly: The FDA label warns that "if after long term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly" 2. Abrupt discontinuation can cause adrenal insufficiency and symptom rebound.

Do not stop antiemetics during the taper: The guideline emphasizes that "corticosteroids should be prescribed in addition to previously started effective antiemetics" 1. Continue first-line agents (cyclizine, promethazine) and second-line agents (ondansetron, metoclopramide) as needed throughout the taper.

Watch for two distinct subtypes: Research identifies "remitting hyperemesis" (resolves by 14-22 weeks, ~80% of cases) versus "full-term hyperemesis" (persists until delivery) 5. If symptoms persist beyond 20 weeks despite tapering attempts, consider that this patient may have the full-term subtype requiring longer steroid maintenance.

If Symptoms Recur During Tapering

If vomiting returns during the taper:

1. Hold at current dose for 1-2 weeks to restabilize
2. Optimize antiemetics before attempting further steroid reduction
3. Consider slower taper (5 mg every 2 weeks instead of weekly)
4. If severe recurrence: May need to increase back to previous effective dose and attempt slower taper later 4

The goal is complete discontinuation by 16-20 weeks gestation in most cases, but individualization based on symptom control is necessary while following the 5-10 mg weekly reduction framework 1, 3.